Streetbeat News

Price Targets

EXAI

Exscientia's stock (EXAI) is trading lower following a downgrade by B of A Securities from Buy to Neutral, with a reduced price target from $11 to $9.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 5:00 pm

CING

HC Wainwright & Co. has reaffirmed its Buy rating on Cingulate Inc (NASDAQ:CING) and increased its price target from $3.50 to $8.00. Cingulate's shares are currently trading at $7.15, down 0.56% over the last 24 hours. The new price target suggests a potential upside of 11.89%. Cingulate is a clinical stage biopharmaceutical company focused on developing pharmaceutical products with its proprietary drug delivery platform.

Portfolio Pulse from Benzinga Insights

January 05, 2024 | 5:00 pm

ALKT

Needham has reaffirmed its Buy rating on Alkami Technology (NASDAQ:ALKT) and increased its price target from $24.00 to $30.00. Alkami's shares are currently trading at $22.81, and the new price target suggests a potential upside of 31.52%. Alkami provides cloud-based digital banking solutions and operates on a proprietary, true cloud-based, multi-tenant architecture.

Portfolio Pulse from Benzinga Insights

January 05, 2024 | 5:00 pm

HII

Barclays has downgraded Huntington Ingalls Industries (HII) from an Overweight to an Equal-Weight rating, while raising the price target from $250.00 to $280.00. HII's shares are currently trading down at $254.71, which is 0.63% lower than the previous day. The new price target suggests a potential upside of 9.93% from the current share price. Huntington Ingalls, spun off from Northrop Grumman in 2011, is a major military shipbuilder in the U.S., known for producing a variety of military ships and providing IT services to government agencies.

Portfolio Pulse from Benzinga Insights

January 05, 2024 | 5:00 pm

CRC

B of A Securities downgraded California Resources (NYSE:CRC) to Neutral from a previous rating, with a new price target of $60.00, down from $64.00. CRC's shares are currently trading at $51.90, down 0.36% over the last 24 hours. The new price target suggests a potential upside of 15.61% from the current share price. California Resources is an independent oil and natural gas company operating in California, known for low carbon intensity production and focusing on decarbonization projects.

Portfolio Pulse from Benzinga Insights

January 05, 2024 | 5:00 pm

PNTG

The Pennant Group, Inc. (PNTG) stock is trading higher following an upgrade by Stephens & Co from Equal-Weight to Overweight, with a new price target set at $18.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 4:58 pm

NVDA

BofA analysts have maintained a Buy rating and a $700 per share price target for NVIDIA (NASDAQ:NVDA), citing the company's potential to generate approximately $100 billion in free cash flow (FCF) in CY24/25E. They believe NVIDIA's dominance in generative AI could drive this significant FCF, which could lead to both organic and inorganic growth opportunities. While they estimate $30-$35 billion could be used for buybacks, the remaining $65-$70 billion could fund new initiatives. The analysts also note NVIDIA's current trading multiple is depressed compared to its historical median, attributing this to uncertainties in CY25 growth prospects and its hardware-dependent business model. They suggest that NVIDIA's strong FCF generation provides the flexibility to address these concerns and potentially increase its trading multiple by building a recurring revenue profile.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 4:56 pm

VTEX

VTEX stock has seen a positive movement after Morgan Stanley upgraded the stock from Equal-Weight to Overweight and increased the price target from $5.5 to $8.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 4:50 pm

DNB

Dun & Bradstreet Holdings' stock (DNB) has seen an uptick in trading after Raymond James upgraded the stock from Outperform to Strong Buy, with a new price target set at $18.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 4:17 pm

AGL

JP Morgan analyst Lisa Gill has downgraded Agilon Health (NYSE:AGL) from Overweight to Neutral and reduced the price target from $17 to $9.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 4:15 pm